Zeit Medical

Based in the US, Zeit Medical is a bioelectronic company focused on innovative brain health monitoring solutions through smart headband technology that continuously tracks brain electrical activity for enhanced neurological injury detection. Zeit Medical, founded in 2019 in Redwood City, US, specializes in bioelectronic solutions for brain health monitoring. The company, co-founded by Orestis Vardoulis, Patrick Thompson, and Urs Naber, has raised a total of USD 2. 000 mn in funding, with the latest Seed funding round completed on October 29, 2021, supported by investors such as SeedToB Capital and Y Combinator.

No significant pivots or changes in business strategy have been noted. Zeit Medical specializes in advanced brain health monitoring solutions through its innovative smart headband technology, which continuously tracks the electrical activity of the brain. This technology is designed to detect neurological injuries by identifying specific patterns in electroencephalography (EEG) readings, similar to how arrhythmias are presented on an electrocardiogram (EKG). By seamlessly integrating with existing EEG systems, the company empowers healthcare providers to diagnose and treat neurological conditions with greater efficiency and precision.

The primary end users include patients at risk of stroke, individuals with traumatic brain injuries, and healthcare professionals across various settings, including hospitals and home care environments. Zeit Medical's solutions are positioned in both the United States and broader markets that experience high incidences of neurological conditions requiring timely intervention. Zeit Medical generates revenue through partnerships with healthcare providers, leveraging its subscription-based model for ongoing access to its monitoring technology. The business transactions involve healthcare institutions purchasing subscriptions or contracts that enable continuous monitoring of multiple patients, along with automated pre-screening and annotation of EEG data.

The pricing structure is aligned with the value provided by its AI capabilities, delivering reliable brain health monitoring. Their flagship product, the smart headband, enhances patient management and recovery while allowing for rapid diagnosis and treatment of neurological injuries. Revenue is derived from direct contracts with hospitals and potentially through collaborative agreements with neurocritical care units and rehabilitation centers. In October 2021, Zeit Medical raised USD 2.

000 mn in Seed funding, which will be used to continue and expand operations, build the team, and fund studies prerequisite to FDA consideration and approval. The company plans to design and launch new products aimed at further enhancing its monitoring capabilities. Additionally, Zeit Medical is targeting expansion into new geographic markets that have critical needs for timely neurological care. The recent funding will support these initiatives and facilitate the company's growth strategy, ensuring that their innovative solutions reach a broader audience in healthcare.